Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Accumulated Expenses (2020 - 2023)

Cullinan Therapeutics has reported Accumulated Expenses over the past 4 years, most recently at $20.9 million for Q3 2023.

  • Quarterly results put Accumulated Expenses at $20.9 million for Q3 2023, up 55.08% from a year ago — trailing twelve months through Sep 2023 was $20.9 million (up 55.08% YoY), and the annual figure for FY2022 was $14.1 million, up 64.8%.
  • Accumulated Expenses for Q3 2023 was $20.9 million at Cullinan Therapeutics, up from $15.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CGEM hit a ceiling of $20.9 million in Q3 2023 and a floor of $4.2 million in Q2 2021.
  • Median Accumulated Expenses over the past 4 years was $11.2 million (2022), compared with a mean of $11.2 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 181.15% in 2022 and later skyrocketed 30.5% in 2023.
  • Cullinan Therapeutics' Accumulated Expenses stood at $4.6 million in 2020, then soared by 84.81% to $8.6 million in 2021, then skyrocketed by 64.8% to $14.1 million in 2022, then soared by 48.19% to $20.9 million in 2023.
  • The last three reported values for Accumulated Expenses were $20.9 million (Q3 2023), $15.5 million (Q2 2023), and $18.4 million (Q1 2023) per Business Quant data.